Home › Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia clinical trials recruiting in the U.S.
8 studies for Acute Lymphocytic Leukemia are recruiting participants at sites across the United States.
Acute Lymphocytic Leukemia (ALL) or Acute Lymphoblastic Leukemia is a cancer of the white blood cells. Learn more about symptoms and treatment.
Cities with the most studies
By state
Recently updated studies
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07566364Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT06580002Halt Aging in Survivors of Blood Cancers
Recruiting
Ages 50 and older · All sexes · Updated Jul 1, 2026 · NCT07292272211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
RecruitingObservational study
Up to age 26 · All sexes · Updated Jun 4, 2026 · NCT05865301A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 28, 2026 · NCT03219450Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RecruitingPhase 2
Ages 1 to 60 · All sexes · Updated Mar 12, 2026 · NCT03970096From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.